TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Kamada ( (IL:KMDA) ).
On December 8, 2025, Kamada Ltd. announced the discontinuation of its Phase 3 InnovAATe trial for Inhaled AAT due to a lack of statistically significant benefit in its primary endpoint. Despite this setback, Kamada reiterated its 2025 revenue guidance and projected double-digit growth in revenues and profitability for 2026, supported by its robust commercial portfolio and expansion plans. The company continues to supply GLASSIA® internationally and is pursuing business development opportunities to sustain long-term growth.
The most recent analyst rating on (IL:KMDA) stock is a Buy with a ILs2471.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.
More about Kamada
Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies. The company markets products for rare and serious conditions, including six FDA-approved specialty plasma-derived products, and is expanding its plasma collection operations. Kamada is focused on organic growth, business development opportunities, and leveraging its financial strength for long-term growth.
YTD Price Performance: 5.38%
Average Trading Volume: 60,588
Technical Sentiment Signal: Buy
Current Market Cap: ILs1.33B
For an in-depth examination of KMDA stock, go to TipRanks’ Overview page.